S&P 500 Telecom Services Sector SPDR (XTL) 64.20 $XTL
15 Most Read ETF Articles of the Week (May 9-13)
etftrends@etftrends.com (ETF Trends) - ETF Trends - Fri May 13, 5:44PM CDT
Each day ETFtrends.com publishes news, strategy and commentary on ETFs in the realms of Commodities, Currency, Equities and Smart-Beta to name a few. Here’s a look at the Top 15 Most Viewed Articles of the Week on ETF Trends, May 9-13, 2016. Click...
SPLV: 41.33 (+0.04), IST: 24.31 (+0.13), OUNZ: 13.02 (+0.01), SIVR: 18.84 (+0.07), SCHH: 42.15 (-0.01), SGOL: 127.87 (+0.10), SOYB: 19.05 (+0.24), JPGE: 52.37 (+0.14), SLV: 18.27 (+0.07), SDOG: 41.00 (-0.08), FXG: 45.81 (-0.13), USMV: 45.26 (+0.05), XTL: 64.20 (-0.79), DVY: 85.28 (-0.23), REZ: 64.90 (+0.22), RWR: 96.24 (-0.02), PBJ: 32.67 (-0.10), FCOM: 29.43 (-0.24), FENY: 18.70 (-0.16), ECON: 24.32 (-0.06), IAU: 12.67 (+0.02), VYM: 71.28 (-0.01), AMLP: 12.23 (-0.06), FRI: 24.00 (unch), IDOG: 23.74 (+0.14), VIG: 82.99 (+0.09), JPEM: 48.27 (+0.21), XLP: 52.82 (+0.14), IYZ: 31.83 (-0.37), FSTA: 31.68 (+0.04), MORT: 22.18 (+0.09), REM: 10.69 (+0.03), IYR: 80.00 (-0.13), EMB: 115.89 (+0.13), ZSL: 28.48 (-0.13), VNQ: 85.61 (-0.13), JPIN: 51.22 (+0.31), XLE: 66.92 (-0.49), IYK: 113.62 (unch), KXI: 98.23 (+0.49), VDE: 92.02 (-1.42), VDC: 135.70 (-0.61), IPS: 43.53 (+0.30), DBA: 20.62 (+0.18), IYE: 37.02 (-0.34), ICF: 104.31 (-0.10), GLD: 125.44 (+0.12), VOX: 92.20 (-1.75), CORN: 18.87 (+0.12), IXP: 60.82 (+0.16), KBWY: 35.47 (-0.38)
6 Telecom ETFs to Dial Into Verizon, AT&T, Vodafone
etftrends@etftrends.com (ETF Trends) - ETF Trends - Mon May 09, 4:01PM CDT
Telecommunications exchange traded funds have enjoyed a strong run this year as income-oriented investors turned to the the attractive dividend-paying sector. The U.S. telecom industry is changing. Consumers are exchanging traditional land lines for...
XTL: 64.20 (-0.79), IYZ: 31.83 (-0.37), LTL: 101.00 (-2.16), IST: 24.31 (+0.13), VOX: 92.20 (-1.75), IXP: 60.82 (+0.16), FCOM: 29.43 (-0.24)
What Lies Ahead for Telecom ETFs in 2016?
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 10:58AM CST
Telecom ETFs are an interesting choice for income orineted, defensive investors.
XTL: 64.20 (-0.79), IYZ: 31.83 (-0.37), VOX: 92.20 (-1.75), FCOM: 29.43 (-0.24), IXP: 60.82 (+0.16)
XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol®
PR Newswire - Wed Jan 13, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has reached agreement with CyDex Pharmaceuticals Inc. (La Jolla, CA) (CyDex) for the use and supply of Captisol® in the formulation of its lead drug, hCDR1, for the treatment of systemic lupus erythematosus (SLE).
XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02)
XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus
PR Newswire - Mon Jan 11, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has submitted the full protocol for its advanced stage clinical trial of hCDR1 for the treatment of systemic lupus erythematosus (SLE) to Yeda Research and Development Company Ltd. (Yeda).
XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02)
2 Reasons Consumer Discretionary ETFs Will Finish 2015 Strong
ETFtrends.com - ETF Trends - Thu Oct 29, 3:00PM CDT
The consumer discretionary sector and related exchange traded funds could benefit the most in an expanding economic environment, with the Federal Reserve gradually raising interest rates. For broad consumer discretionary exposure, investors can...
XTL: 64.20 (-0.79), XLY: 78.51 (+0.06), XLV: 72.07 (+0.22)
XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015
PR Newswire - Mon Oct 26, 8:15AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, announced today that its Chief Executive Officer, Josh Levine, will be presenting at BIO-Europe 2015, being held at the International Congress Center (ICM) in Munich, Germany.
XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02)
XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset
PR Newswire - Tue Oct 13, 7:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. ("Yeda" to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE).
XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02)
Q4 Outlook for Telecom ETFs
Zacks Equity Research - Zacks Investment Research - Thu Sep 24, 11:46AM CDT
The rising demand for technologically superior products has been a silver lining for the telecom industry in an otherwise tough environment.
XTL: 64.20 (-0.79), IYZ: 31.83 (-0.37), VOX: 92.20 (-1.75), FCOM: 29.43 (-0.24), IXP: 60.82 (+0.16)
Who Will Get Hurt the Worst This Earnings Season?
Dan Caplinger, The Motley Fool - Motley Fool - Tue Sep 15, 5:40AM CDT
The energy industry is at ground zero of the earnings downturn. Image: Flickr/Lindsey G. The lifeblood of the stock market is corporate earning power, and so far in 2015, the upward momentum that the U.S. economy has seen throughout most of the...
XTL: 64.20 (-0.79), XLE: 66.92 (-0.49)
XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC
PR Newswire - Thu Sep 03, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that its Chief Executive Officer, Josh Levine, will be presenting at The Rodman & Renshaw 17th Annual Global Investment Conference being held at the St. Regis Hotel in New York.
XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02)
XTL Biopharmaceuticals Reports Second Quarter 2015 Results
PR Newswire - Tue Sep 01, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company", a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today provided its financial and operational results for the second quarter and the six months ended June 30, 2015.
XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02), NVS: 81.06 (+1.12)
Talking Telecom ETF Opportunity
ETFtrends.com - ETF Trends - Thu Jun 18, 1:25PM CDT
Among sector exchange traded funds, telecom ETFs are usually the smallest and most overlooked, factors that belie occasional opportunity with this slow-growth group. The SPDR S&P Telecom ETF (NYSEArca: XTL ) is one telecom ETF that currently...
XTL: 64.20 (-0.79)
A Beginner's Guide to Telecom ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Jun 18, 12:55PM CDT
Investors seeking to tap the growth potential and attractive yields of the telecom sector may take a closer look at these ETF.
XTL: 64.20 (-0.79), IYZ: 31.83 (-0.37), VOX: 92.20 (-1.75), FCOM: 29.43 (-0.24), IXP: 60.82 (+0.16)
15 Most Read ETF Articles of the Week (May 9-13)
etftrends@etftrends.com (ETF Trends) - ETF Trends - Fri May 13, 5:44PM CDT
Each day ETFtrends.com publishes news, strategy and commentary on ETFs in the realms of Commodities, Currency, Equities and Smart-Beta to name a few. Here’s a look at the Top 15 Most Viewed Articles of the Week on ETF Trends, May 9-13, 2016. Click...
SPLV: 41.33 (+0.04), IST: 24.31 (+0.13), OUNZ: 13.02 (+0.01), SIVR: 18.84 (+0.07), SCHH: 42.15 (-0.01), SGOL: 127.87 (+0.10), SOYB: 19.05 (+0.24), JPGE: 52.37 (+0.14), SLV: 18.27 (+0.07), SDOG: 41.00 (-0.08), FXG: 45.81 (-0.13), USMV: 45.26 (+0.05), XTL: 64.20 (-0.79), DVY: 85.28 (-0.23), REZ: 64.90 (+0.22), RWR: 96.24 (-0.02), PBJ: 32.67 (-0.10), FCOM: 29.43 (-0.24), FENY: 18.70 (-0.16), ECON: 24.32 (-0.06), IAU: 12.67 (+0.02), VYM: 71.28 (-0.01), AMLP: 12.23 (-0.06), FRI: 24.00 (unch), IDOG: 23.74 (+0.14), VIG: 82.99 (+0.09), JPEM: 48.27 (+0.21), XLP: 52.82 (+0.14), IYZ: 31.83 (-0.37), FSTA: 31.68 (+0.04), MORT: 22.18 (+0.09), REM: 10.69 (+0.03), IYR: 80.00 (-0.13), EMB: 115.89 (+0.13), ZSL: 28.48 (-0.13), VNQ: 85.61 (-0.13), JPIN: 51.22 (+0.31), XLE: 66.92 (-0.49), IYK: 113.62 (unch), KXI: 98.23 (+0.49), VDE: 92.02 (-1.42), VDC: 135.70 (-0.61), IPS: 43.53 (+0.30), DBA: 20.62 (+0.18), IYE: 37.02 (-0.34), ICF: 104.31 (-0.10), GLD: 125.44 (+0.12), VOX: 92.20 (-1.75), CORN: 18.87 (+0.12), IXP: 60.82 (+0.16), KBWY: 35.47 (-0.38)
6 Telecom ETFs to Dial Into Verizon, AT&T, Vodafone
etftrends@etftrends.com (ETF Trends) - ETF Trends - Mon May 09, 4:01PM CDT
Telecommunications exchange traded funds have enjoyed a strong run this year as income-oriented investors turned to the the attractive dividend-paying sector. The U.S. telecom industry is changing. Consumers are exchanging traditional land lines for...
XTL: 64.20 (-0.79), IYZ: 31.83 (-0.37), LTL: 101.00 (-2.16), IST: 24.31 (+0.13), VOX: 92.20 (-1.75), IXP: 60.82 (+0.16), FCOM: 29.43 (-0.24)
What Lies Ahead for Telecom ETFs in 2016?
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 10:58AM CST
Telecom ETFs are an interesting choice for income orineted, defensive investors.
XTL: 64.20 (-0.79), IYZ: 31.83 (-0.37), VOX: 92.20 (-1.75), FCOM: 29.43 (-0.24), IXP: 60.82 (+0.16)
XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol®
PR Newswire - Wed Jan 13, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has reached agreement with CyDex Pharmaceuticals Inc. (La Jolla, CA) (CyDex) for the use and supply of Captisol® in the formulation of its lead drug, hCDR1, for the treatment of systemic lupus erythematosus (SLE). XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02)
XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus
PR Newswire - Mon Jan 11, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has submitted the full protocol for its advanced stage clinical trial of hCDR1 for the treatment of systemic lupus erythematosus (SLE) to Yeda Research and Development Company Ltd. (Yeda). XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02)
2 Reasons Consumer Discretionary ETFs Will Finish 2015 Strong
ETFtrends.com - ETF Trends - Thu Oct 29, 3:00PM CDT
The consumer discretionary sector and related exchange traded funds could benefit the most in an expanding economic environment, with the Federal Reserve gradually raising interest rates. For broad consumer discretionary exposure, investors can...
XTL: 64.20 (-0.79), XLY: 78.51 (+0.06), XLV: 72.07 (+0.22)
XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015
PR Newswire - Mon Oct 26, 8:15AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, announced today that its Chief Executive Officer, Josh Levine, will be presenting at BIO-Europe 2015, being held at the International Congress Center (ICM) in Munich, Germany. XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02)
XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset
PR Newswire - Tue Oct 13, 7:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. ("Yeda" to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE). XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02)
Q4 Outlook for Telecom ETFs
Zacks Equity Research - Zacks Investment Research - Thu Sep 24, 11:46AM CDT
The rising demand for technologically superior products has been a silver lining for the telecom industry in an otherwise tough environment.
XTL: 64.20 (-0.79), IYZ: 31.83 (-0.37), VOX: 92.20 (-1.75), FCOM: 29.43 (-0.24), IXP: 60.82 (+0.16)
Who Will Get Hurt the Worst This Earnings Season?
Dan Caplinger, The Motley Fool - Motley Fool - Tue Sep 15, 5:40AM CDT
The energy industry is at ground zero of the earnings downturn. Image: Flickr/Lindsey G. The lifeblood of the stock market is corporate earning power, and so far in 2015, the upward momentum that the U.S. economy has seen throughout most of the...
XTL: 64.20 (-0.79), XLE: 66.92 (-0.49)
XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC
PR Newswire - Thu Sep 03, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that its Chief Executive Officer, Josh Levine, will be presenting at The Rodman & Renshaw 17th Annual Global Investment Conference being held at the St. Regis Hotel in New York. XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02)
XTL Biopharmaceuticals Reports Second Quarter 2015 Results
PR Newswire - Tue Sep 01, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today provided its financial and operational results for the second quarter and the six months ended June 30, 2015. XTL: 64.20 (-0.79), XTLB: 1.02 (-0.02), NVS: 81.06 (+1.12)
Talking Telecom ETF Opportunity
ETFtrends.com - ETF Trends - Thu Jun 18, 1:25PM CDT
Among sector exchange traded funds, telecom ETFs are usually the smallest and most overlooked, factors that belie occasional opportunity with this slow-growth group. The SPDR S&P Telecom ETF (NYSEArca: XTL ) is one telecom ETF that currently...
XTL: 64.20 (-0.79)
A Beginner's Guide to Telecom ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Jun 18, 12:55PM CDT
Investors seeking to tap the growth potential and attractive yields of the telecom sector may take a closer look at these ETF.
XTL: 64.20 (-0.79), IYZ: 31.83 (-0.37), VOX: 92.20 (-1.75), FCOM: 29.43 (-0.24), IXP: 60.82 (+0.16)
